STOCK TITAN

Selecta Biosciences to Participate at the 21st Annual Needham Virtual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

On April 4, 2022, Selecta Biosciences (NASDAQ: SELB) announced its participation in the 21st Annual Needham Virtual Healthcare Conference from April 11-14, 2022. The company will hold a fireside chat and engage in one-on-one investor meetings. The chat is scheduled for April 14, 2022, at 1:30 p.m. EST. Interested parties can access a live webcast through Selecta's website. Selecta operates using its clinically validated ImmTOR® platform to develop therapies that address unwanted immune responses.

Positive
  • None.
Negative
  • None.

WATERTOWN, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Company’s Management will participate in a fireside chat and one-on-one investor meetings at the 21st Annual Needham Virtual Healthcare Conference, to be held virtually April 11-14, 2022.

21st Annual Needham Virtual Healthcare Conference
Format: Fireside chat and one-on-one investor meetings
Date: Thursday April 14, 2022
Time: 1:30 p.m. EST
Webcast: Click Here

An archived webcast will also be accessible in the Investors & Media section of the company’s website at www.selectabio.com.

About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR® platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit www.selectabio.com.

For Investors:
Bruce Mackle
LifeSci Advisors, LLC
+1-929-469-3859
bmackle@lifesciadvisors.com

For Media: 
Brittany Leigh, Ph.D.
LifeSci Communications, LLC
+1-646-751-4366
bleigh@lifescicomms.com 


FAQ

What is the date of the Needham Virtual Healthcare Conference for Selecta Biosciences (SELB)?

Selecta Biosciences will participate in the Needham Virtual Healthcare Conference from April 11-14, 2022.

When will Selecta Biosciences' fireside chat occur during the conference?

The fireside chat for Selecta Biosciences is scheduled for April 14, 2022, at 1:30 p.m. EST.

How can I access the webcast for Selecta Biosciences' fireside chat?

You can access the live webcast through Selecta Biosciences' website during the chat.

What platform does Selecta Biosciences use for its therapies?

Selecta Biosciences leverages its clinically validated ImmTOR® platform to develop tolerogenic therapies.

What types of therapies is Selecta Biosciences focusing on?

Selecta Biosciences focuses on developing therapies for enzyme therapies, gene therapies, and autoimmune diseases.

Selecta Biosciences, Inc.

NASDAQ:SELB

SELB Rankings

SELB Latest News

SELB Stock Data

135.20M
94.00M
25.06%
47.78%
5.2%
Biotechnology
Healthcare
Link
United States
Watertown